Purgo's Technology
Purgo Pouch consists of a rate-controlled membrane that allows for passive diffusion of antibiotic over a concentration gradient, no pumps or batteries required. The pouch is attached to a catheter that is exteriorized prior to wound closure to allow for dosing. Every 24 hours, the residual fluid in the pouch is removed and fresh antibiotics are placed inside the pouch for up to 30 days. When treatment is complete the pouch is completely emptied and removed out of the exteriorization site just like a surgical drain.
The Challenge: Surgical Site Infections
By the Numbers in the U.S.
Surgical Site Infections Cost the U.S. Healthcare System
$10 BILLION ANNUALLY
And Impact Over 300,000 Patients a Year
#1
Cause of Healthcare Acquired Infections
9,000
Number of U.S. Patients that Die From SSI Annually
#1
Cause of Readmissions After Surgery
9.7
Average Number of Days in Hospital Due to SSI
Surgical Site Infection
By the Numbers in the U.S.
Surgical Site Infections Cost the U.S. Healthcare System
$10 BILLION ANNUALLY
And Impact Over 300,000 Patients a Year
#1
Cause of Healthcare Acquired Infections
9,000
Number of U.S. Patients that Die From SSI Annually
#1
Cause of Readmissions After Surgery
9.7
Average Number of Days in Hospital Due to SSI
Surgical Site Infection
By the Numbers in the U.S.
Surgical Site Infections Cost the U.S. Healthcare System
$10 BILLION ANNUALLY
And Impact Over 300,000 Patients a Year
#1
Cause of Healthcare Acquired Infections
9,000
Number of U.S. Patients that Die From SSI Annually
#1
Cause of Readmissions After Surgery
9.7
Average Number of Days in Hospital Due to SSI
Causes Of Infection
Planktonic vs Biofilm
What Are Planktonic Bacteria?
- Individual bacteria.
- Float in a liquid medium like blood.
- Metabolically active.
- More susceptible to antibiotics.
- Readily controlled by host immune cells.
What Are Bacterial Biofilms?
- Communities of bacteria.
- Primarily attach to solid surfaces.
- Metabolically inactive.
- Less susceptible to antibiotics.
- Can cause recurring infections.
What are Planktonic Bacteria?
- Individual bacteria.
- Float in a liquid medium like blood.
- Metabolically active.
- More susceptible to antibiotics.
- Readily controlled by host immune cells.
What are Bacterial Biofilms?
- Communities of bacteria.
- Primarily attach to solid surfaces.
- Metabolically inactive.
- Less susceptible to antibiotics.
- Can cause recurring infections.
What are Planktonic Bacteria?
- Individual bacteria.
- Float in a liquid medium like blood.
- Metabolically active.
- More susceptible to antibiotics.
- Readily controlled by host immune cells.
What are Bacterial Biofilms?
- Communities of bacteria.
- Primarily attach to solid surfaces.
- Metabolically inactive.
- Less susceptible to antibiotics.
- Can cause recurring infections.
The Solution: Purgo Pouch
The Right Therapy
Purgo Pouch will deliver an effective tobramycin dose to kill biofilms.
The Right Place
Purgo Pouch targets infection by delivering tobramycin locally in the surgical wound site.
The Right Duration
Purgo Pouch sustains tobramycin delivery for up to 30 days, offering unparallelled versatility.
The Solution
The Right Therapy
Purgo Pouch will deliver an effective tobramycin dose to kill biofilms.
The Right Place
Purgo Pouch targets infection by delivering tobramycin locally in the surgical wound site.
The Right Duration
Purgo Pouch sustains tobramycin delivery for up to 30 days, offering unparallelled versatility.
Purgo Pouch Is Superior To Current Clinical Approaches
SSI Treatment Options
Purgo Pouch Sustained Delivery Device*
Oral Antibiotic Administration
IV Antibiotic Administration
Antibiotic-Impregnated Beads
Local Antibiotic Powder or Lavage Application
Effective Planktonic Bacterial Control
Flexibility to Change Antibiotics
Continuous Daily Therapy
Effective Biofilm Eradication
*As shown in preclinical studies
Purgo Pouch Is Superior To Current Clinical Approaches
SSI Treatment Options
Purgo Pouch Sustained Delivery Device*
Effective Planktonic Bacterial Control
Flexibility to Change Antibiotics
Continuous Daily Therapy
Effective Biofilm Eradication
Oral Antibiotic Administration
Effective Planktonic Bacteria Control
Flexibility to Change Antibiotics
Continuous Daily Therapy
Effective Biofilm Eradication
IV Antibiotic Administration
Effective Planktonic Bacteria Control
Flexibility to Change Antibiotics
Continuous Daily Therapy
Effective Biofilm Eradication
Antibiotic-Impregnated Beads
Effective Planktonic Bacteria Control
Flexibility to Change Antibiotics
Continuous Daily Therapy
Effective Biofilm Eradication
Local Antibiotic Powder or Lavage Application
Effective Planktonic Bacteria Control
Flexibility to Change Antibiotics
Continuous Daily Therapy
Effective Biofilm Eradication
*As shown in preclinical studies
Purgo’s Pipeline
Orthopedic surgical site infection – treatment
Manage surgical site infections that affect bone such as in open fractures
Product/Platform
Discovery
Pre-clinical
Phase 1
Orthopedic surgical site infection – prophylaxis
Prevent surgical site infections from developing in, for example, open fractures
Product/Platform
Discovery
Pre-clinical
Phase 1
General surgical site infection – treatment
Manage infection present in soft tissue spaces
Product/Platform
Discovery
Pre-clinical
Phase 1
General surgical site infection – prophylaxis
Prevent infection from developing in soft tissue spaces
Product/Platform
Discovery
Pre-clinical
Phase 1
Pain management – post-operative
Provide post-surgical pain relief via sustained local anesthetic delivery
Product/Platform
Discovery
Pre-clinical
Phase 1
Oncology – solid tumors
Target tumors with local delivery of multimodal synergistic small molecule and/or antibody combinations (reduced systemic toxicity)
Product/Platform
Discovery
Pre-clinical
Phase 1
Bone growth and fracture healing – expedite
Locally deliver bone growth agents (bone morphogenetic protein) expediting fracture healing and bone growth in other applications
Product/Platform
Discovery
Pre-clinical
Phase 1